It is important to notice that these events are not solely limited to oncology patients because erythropoietin‐stimulating agents have been associated with polycythemia, hypertension, thrombocytosis, platelet hyperactivity, and activation of blood coagulation, all of which are thrombogenic.53, 54. The gene discussed is EPO; the disease is thrombocytosis disease.